INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 212 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is 1.87 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,308 | +39.5% | 178,438 | -16.7% | 0.00% | 0.0% |
| Q2 2023 | $2,371 | +51.1% | 214,253 | +83.4% | 0.00% | +100.0% |
| Q1 2023 | $1,569 | -20.7% | 116,826 | -27.0% | 0.00% | 0.0% |
| Q4 2022 | $1,979 | -99.9% | 159,968 | -0.9% | 0.00% | -50.0% |
| Q3 2022 | $2,252,000 | +355.9% | 161,495 | +351.8% | 0.00% | – |
| Q2 2022 | $494,000 | -61.8% | 35,743 | -55.0% | 0.00% | -100.0% |
| Q1 2022 | $1,292,000 | -5.8% | 79,384 | -5.7% | 0.00% | – |
| Q4 2021 | $1,372,000 | +363.5% | 84,158 | +321.4% | 0.00% | – |
| Q3 2021 | $296,000 | -79.4% | 19,969 | -72.2% | 0.00% | -100.0% |
| Q2 2021 | $1,435,000 | -38.4% | 71,874 | -28.7% | 0.00% | 0.0% |
| Q1 2021 | $2,328,000 | +1.2% | 100,866 | +8.3% | 0.00% | 0.0% |
| Q4 2020 | $2,300,000 | -81.4% | 93,137 | -68.8% | 0.00% | -85.7% |
| Q3 2020 | $12,382,000 | +22.3% | 298,613 | +41.4% | 0.01% | -12.5% |
| Q2 2020 | $10,122,000 | -37.3% | 211,246 | -17.6% | 0.01% | -33.3% |
| Q1 2020 | $16,135,000 | +54.6% | 256,273 | +204.4% | 0.01% | +100.0% |
| Q4 2019 | $10,434,000 | +249.0% | 84,199 | +86.8% | 0.01% | +200.0% |
| Q3 2019 | $2,990,000 | -25.6% | 45,063 | -10.8% | 0.00% | 0.0% |
| Q2 2019 | $4,019,000 | -87.8% | 50,503 | -82.8% | 0.00% | -91.3% |
| Q1 2019 | $32,868,000 | +225.2% | 293,838 | +193.0% | 0.02% | +228.6% |
| Q4 2018 | $10,107,000 | -12.1% | 100,285 | +10.2% | 0.01% | -12.5% |
| Q3 2018 | $11,502,000 | +114.5% | 91,017 | +42.4% | 0.01% | +60.0% |
| Q2 2018 | $5,362,000 | +0.4% | 63,916 | -26.4% | 0.01% | +25.0% |
| Q1 2018 | $5,340,000 | -20.3% | 86,809 | -24.3% | 0.00% | -20.0% |
| Q4 2017 | $6,697,000 | +128.8% | 114,655 | +127.4% | 0.01% | +66.7% |
| Q3 2017 | $2,927,000 | -7.6% | 50,430 | +92.6% | 0.00% | -25.0% |
| Q2 2017 | $3,169,000 | -79.7% | 26,185 | -81.0% | 0.00% | -75.0% |
| Q1 2017 | $15,615,000 | +65.8% | 138,074 | +59.3% | 0.02% | +60.0% |
| Q4 2016 | $9,420,000 | +63.1% | 86,698 | +147.1% | 0.01% | +66.7% |
| Q3 2016 | $5,777,000 | -15.5% | 35,089 | -26.8% | 0.01% | -25.0% |
| Q2 2016 | $6,839,000 | +13.2% | 47,924 | +1.5% | 0.01% | -11.1% |
| Q1 2016 | $6,043,000 | +6689.9% | 47,205 | +7887.3% | 0.01% | – |
| Q4 2015 | $89,000 | -92.2% | 591 | -91.4% | 0.00% | -100.0% |
| Q3 2015 | $1,140,000 | +1325.0% | 6,910 | +1981.3% | 0.00% | – |
| Q2 2015 | $80,000 | -97.2% | 332 | -96.8% | 0.00% | -100.0% |
| Q1 2015 | $2,899,000 | -80.3% | 10,281 | -89.1% | 0.00% | -80.0% |
| Q4 2014 | $14,739,000 | +52.7% | 94,489 | +131.1% | 0.02% | +66.7% |
| Q3 2014 | $9,651,000 | -13.9% | 40,895 | -13.9% | 0.01% | -18.2% |
| Q2 2014 | $11,206,000 | -75.8% | 47,480 | -66.3% | 0.01% | -78.8% |
| Q1 2014 | $46,396,000 | +4799.3% | 141,020 | +912.3% | 0.05% | +5100.0% |
| Q4 2013 | $947,000 | +432.0% | 13,931 | +438.3% | 0.00% | – |
| Q3 2013 | $178,000 | +1086.7% | 2,588 | +689.0% | 0.00% | – |
| Q2 2013 | $15,000 | – | 328 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |